Dr. Ke Shi of Mengying Ophthalmology Honored as 2024 CFS Healthcare Innovation Leader for Pioneering GODS System and AI-Driven Eye Care Solutions

Beijing, China, July 25, 2024—Dr. Shi Ke, Partner and Deputy General Manager of Medical Affairs at Mengying Eye Care, was invited to attend the 13th Financial Summit and give an interview. In recognition of his innovations in the Mengying GODS product system and AI-driven service models, Dr. Shi was jointly named one of the “2024 Healthcare Innovation Leaders” at the 13th Financial Summit, alongside Yu Qingming, Chairman of Sinopharm Group Holdings; Yuan Qianhui, Chairman and CEO of Ankangtong, China’s largest elderly care services enterprise; Gao Shang, Chairman of Gerui Technology, the inventor of the world’s first animal live-surgery “Newton” robotic system; and Xu Ke, Chairman of Jinghong Group, an emerging national digital chain brand for medical sterilization services.

Established in 2012, the CFS Financial Summit is a premier event brand forged through the collective efforts of numerous domestic financial and mass media outlets. Through diverse formats including keynote speeches, high-level dialogues, in-depth knowledge sharing, tribute ceremonies, and brand exhibitions, the summit convenes and disseminates business wisdom to explore the drivers behind China’s economic transformation and development. Over the past thirteen years, it has evolved into one of the most influential platforms for intellectual exchange in China’s economic landscape.

Dr. Shi Ke was honored as a "2024 Healthcare Innovation Leader" in the field of medical optometry. Leveraging his extensive clinical experience and profound academic background, he has guided Mengying Eye Care toward higher-level development with a forward-looking vision. In particular, Dr. Shi’s GODS Comprehensive Myopia Prevention and Control System, developed based on the causes and consequences of myopia, has received high acclaim. Furthermore, drawing on years of clinical expertise and academic research in ophthalmology, Dr. Shi has transformed traditional optometric service methodologies by integrating artificial intelligence (AI) into ophthalmic diagnosis and treatment workflows. This innovation enables eye clinics to automatically collect data and generate AI-driven diagnostic and treatment reports during patient consultations, providing parents with a clear understanding of their children’s past, present, and future visual development, while also enhancing the operational efficiency and convenience of eye care clinics.

During an interview with the media delegation of the Financial Summit, Dr. Shi Ke shared the development journey and innovative philosophy of Mengying Eye Care. He stated, “Since its inception, Mengying Eye Care has consistently adhered to a customer-centric service philosophy, continuously exploring technological innovations and optimizing service models, particularly through the innovation of its GODS product system and AI-driven service innovations.” The following are the detailed contents of the interview:

When asked about the differences between Mengying Eye Care’s solutions and traditional optometry, Dr. Shi Ke explained that Mengying Eye Care adopts a one-stop holistic solution. Based on the causes of myopia—genetic factors, outdoor activity levels, environmental conditions, and near-work habits—as well as the resulting issues such as decreased distance visual acuity and accommodative lag, the company has developed the GODS product and service system. This system includes genetic testing to assist in diagnosing myopia risk; optical correction, encompassing various methods such as orthokeratology lenses; pharmaceutical and digital therapies, including atropine and visual function training; and services aimed at improving study habits. This systematic treatment approach ensures the scientific rigor and precision of the solutions.

For example, in children who have worn orthokeratology lenses for an extended period but exhibit suboptimal axial length control, genetic testing may reveal specific gene variants that could compromise correction efficacy. In such cases, the treatment plan would be adjusted to spectacles based on point diffusion technology, supplemented with visual function training and related services. Meanwhile, for children with a family history of high myopia, genetic testing may indicate a high risk of developing high myopia in the future. Even if their current refractive error is mild, combined preventive and control measures should be implemented as early as possible to minimize trial-and-error costs and maximize the window for effective myopia management.

To address the scarcity of medical resources, Mengying Ophthalmology leverages AI technology to enhance its service capabilities. During the pre-consultation phase, the Xiao Ying Eye Health Assistant provides interpretation of optometry reports, offers eye health consultations, and assesses children’s risk of myopia. During examinations, AI-assisted diagnosis is employed to improve diagnostic accuracy and efficiency. On the physician side, a large language model-based clinical decision support system is applied to help doctors make more precise treatment decisions. Furthermore, Mengying Ophthalmology has established a three-tier quality control system to ensure service quality and effectively mitigate the shortage of professional personnel.

The host asked how Mengying Eye Care balances parents’ anxiety over their children’s eye health with the constraints of physicians’ busy schedules. Dr. Shi Ke responded that public medical institutions commonly face the challenge of limited consultation time between doctors and patients. To address this issue, Mengying Eye Care leverages AI technology to alleviate physicians’ workload while simultaneously answering parents’ questions.

During the pre-consultation phase, Mengying Ophthalmology’s “Little Eagle Eye” health assistant collects information on children’s symptoms and eye-use habits through interactive Q&A, providing personalized recommendations and myopia prevention and control knowledge. Parents can also access educational animations and videos via a chatbot to enhance their understanding of myopia prevention and control. At the clinic, optometric consultants conduct detailed consultations and examinations, while doctors can review reports through an automated system. During the consultation, a detailed assessment report based on the examination results is pushed to parents’ mobile phones, helping them understand professional terminology and their child’s current refractive status. Post-consultation, MOIN AI provides personalized after-sales consulting and 24/7 customer support, reducing unnecessary return visits to the clinic, and collects feedback through surveys to improve services.

Regarding future planning, Mengying Eye Care will focus on two key areas: First, optimizing the MOIN AI diagnostic and treatment system, which is centered on artificial intelligence, by integrating professional resources and generative AI technologies to build a multi-layered knowledge graph, thereby enhancing the patient experience. Second, deepening collaborations with top-tier hospitals to learn from the clinical expertise of leading specialists, strengthening the medical decision-making capabilities of MOIN AI, and enabling more children to access high-quality eye health services. Furthermore, Mengying Eye Care will continue to develop educational products and services, such as Mengying eye health-themed cultural and creative merchandise and the “Vision Dynamics Camp,” aiming to cultivate children’s correct values and outlook on life. These initiatives will be gradually introduced to the market to benefit a broader population.

Dr. Shi Ke’s award not only recognizes his personal achievements but also affirms the Mengying Eye Care team’s relentless pursuit of innovation. With Mengying Eye Care’s continuous breakthroughs and development in the field of medical optometry, we have every reason to believe that this young and dynamic enterprise will go further and reach greater heights in the future.